Even B, Fayad‐Kobeissi S, Gagliolo JM, et al. Heme oxygenase‐1 induction attenuates senescence in chronic obstructive pulmonary disease lung fibroblasts by protecting against mitochondria dysfunction. Aging Cell. 2018;17:e12837 10.1111/acel.12837

1. INTRODUCTION {#acel12837-sec-0001}
===============

Chronic obstructive pulmonary disease (COPD) represents the fourth leading cause of death worldwide (Mannino & Buist, [2007](#acel12837-bib-0021){ref-type="ref"}). This pathologic state is characterized by airways remodeling and destruction of the alveolar wall, a condition called emphysema. Both processes lead to an irreversible airflow obstruction, which is the hallmark of the disease. Cigarette smoke (CS) exposure is the main risk factor for COPD (Yoshida & Tuder, [2007](#acel12837-bib-0033){ref-type="ref"}). CS contains a high concentration of reactive oxygen species (ROS, 10^17^/puff) and thus plays a major role in promoting oxidative stress in COPD (Church & Pryor, [1985](#acel12837-bib-0008){ref-type="ref"}), (Carnevali et al., [2003](#acel12837-bib-0007){ref-type="ref"}). Oxidative stress provokes inflammation and participates in the emergence of cell senescence, another major feature of this disease (Barnes, [2017](#acel12837-bib-0004){ref-type="ref"}).

Cell senescence can stem from shortening of telomeres during continuous cell replication (replicative senescence) or be triggered by other stressors, such as oxidative stress inducers (hydrogen peroxide, CS) or inflammatory mediators (premature senescence; Nyunoya et al., [2009](#acel12837-bib-0025){ref-type="ref"}). These stimuli can act through two main different pathways: p53‐p21 and p16‐retinoblastoma protein (pRb), respectively (Campisi, [2005](#acel12837-bib-0006){ref-type="ref"}). In the lung, cell senescence leads to a decreased regenerative capacity and an increased cytokine production by structural cells (epithelium, fibroblasts) through a senescence‐associated secretome (Amsellem et al., [2011](#acel12837-bib-0002){ref-type="ref"}; Dagouassat et al., [2013](#acel12837-bib-0009){ref-type="ref"}; Noureddine et al., [2011](#acel12837-bib-0024){ref-type="ref"}; Tsuji, Aoshiba, & Nagai, [2010](#acel12837-bib-0031){ref-type="ref"}). However, other mechanisms, including mitochondrial dysfunction and defective mitophagy, may also contribute to ROS‐mediated senescence in COPD (Lerner, Sundar, & Rahman, [2016](#acel12837-bib-0019){ref-type="ref"}).

Mitophagy is a protective mechanism which minimizes the proportion of dysfunctional mitochondria. This mechanism involves the stabilization of PTEN‐induced putative kinase 1 (PINK‐1) on the outer membrane of mitochondria following the loss of ΔΨm (Matsuda et al., [2010](#acel12837-bib-0022){ref-type="ref"}). The E3 ligase Parkin is then recruited to catalyze K63‐linked ubiquitination of outer membrane proteins. This event facilitates the targeting of mitochondria to form autophagosomes (Hattori, Saiki, & Imai, [2014](#acel12837-bib-0013){ref-type="ref"}). PINK1 and Parkin knockout mice exhibit increased ROS levels and dysfunctional mitochondria (Gispert et al., [2009](#acel12837-bib-0012){ref-type="ref"}; Palacino et al., [2004](#acel12837-bib-0026){ref-type="ref"}) and bronchial epithelial deleted from Parkin or PINK1 exposed to CS display an enhanced mtROS production and cellular senescence (Ito et al., [2015](#acel12837-bib-0018){ref-type="ref"}). These results reinforce the role of oxidative stress as an inducer of cell senescence upon CS exposure and suggest that an impaired mitophagy could be a mechanism inducing ROS‐mediated cell senescence in COPD.

Indeed, defective mitophagy has been already involved in lung cellular senescence upon exposure to CS in vitro and in vivo (Ahmad et al., [2015](#acel12837-bib-0001){ref-type="ref"}).

Among the battery of cellular responses against oxidative stress damage, heme oxygenase (HO)‐1, the inducible isoform of heme oxygenase, plays a critical role in defending the lung against inflammatory and oxidant‐induced cellular and tissue injury. HO‐1 catalyzes heme degradation to produce equimolar amounts of carbon monoxide (CO), which exhibits anti‐inflammatory properties, and biliverdin which is converted to bilirubin, a powerful antioxidant, by biliverdin reductase. In addition, HO‐1 and CO induce mitochondrial biogenesis (Piantadosi et al., [2011](#acel12837-bib-0027){ref-type="ref"}) and recent findings indicate that this system is also implicated in mitochondrial quality control (Hull et al., [2016](#acel12837-bib-0017){ref-type="ref"}). The expression of HO‐1 is induced in smokers with mild COPD as compared to smoker controls (Maestrelli et al., [2001](#acel12837-bib-0020){ref-type="ref"}), revealing a potential protective role of this enzyme against oxidative stress‐mediated cell senescence and mitochondrial dysfunction in COPD. However, to the best of our knowledge, this hypothesis has not been examined yet.

Therefore, in the present study, we investigated whether pharmacological induction of HO‐1 by chronic hemin treatment attenuates senescence and rescues an impaired mitophagy of pulmonary fibroblasts from COPD patients.

2. RESULTS {#acel12837-sec-0002}
==========

2.1. Patient's clinical and demographic features {#acel12837-sec-0003}
------------------------------------------------

Results from fibroblasts from COPD patients were compared with those obtained in fibroblasts from smokers without COPD (S‐C group). The clinical and demographic features of the subjects in the two groups are presented in Table [1](#acel12837-tbl-0001){ref-type="table"}. The two groups were similar in age and smoking history. Subjects with COPD displayed a mild to moderate degree of disease as revealed by GOLD stages I and II (4 and 10 subjects, respectively) and an emphysema score of 45.6 ± 4.5 over 100 (Bankier, De Maertelaer, Keyzer, & Gevenois, [1999](#acel12837-bib-0003){ref-type="ref"}).

###### 

Patient characteristics

  -----------------------------------------------------------------------------------------------------------------
                               Smokers (S‐C)   COPD smokers                                              *p*value
  ---------------------------- --------------- --------------------------------------------------------- ----------
  Patients (*n*)               13              14                                                        

  Age (years)                  57 (48--67)     60 (51--74)                                               ns

  Sex (M/F)                    6/7             7/7                                                       

  FEV~1~/VC                    81 (72/107)     61 (42/69)[\*\*\*](#acel12837-note-0006){ref-type="fn"}   \<0.001

  FEV~1~ (%)                   89 (76--113)    73 (50--113)[\*\*](#acel12837-note-0005){ref-type="fn"}   \<0.001

  GOLD (*n*)\                  13/0/0/0/0      0/4/10/0/0                                                
  0/I/II/III/IV                                                                                          

  Smoking history (pack‐yrs)   43 (30--60)     46 (20--75)                                               ns

  Emphysema score (%)          12.9 ± 3.5      45.3 ± 4.6[\*\*](#acel12837-note-0005){ref-type="fn"}     \<0.001
  -----------------------------------------------------------------------------------------------------------------

COPD: chronic obstructive pulmonary disease; GOLD: Global Initiative for Chronic Obstructive Lung Disease; VC: vital capacity; FEV~1~, forced expiratory volume in 1 s.

Emphysema score was assessed on 0%--100% scale.

Data are expressed as median with minimum and maximum quartiles (in parentheses), except for emphysema score, which is expressed as mean ± SEM.

\*\**p* \< 0.01.

\*\*\**p* \< 0.001 COPD patients vs. smokers.
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2.2. Hemin induces gene, protein expression, and activity of HO‐1 {#acel12837-sec-0004}
-----------------------------------------------------------------

To investigate the role of hemin and HO‐1 in counteracting fibroblasts senescence, we established a protocol for long‐term exposure of cells to nontoxic concentrations of hemin. We found that cells treated every two days with hemin exhibited higher *HMOX1* gene expression (Figure [1](#acel12837-fig-0001){ref-type="fig"}a), which was reflected in an increased level of heme oxygenase activity (Figure [1](#acel12837-fig-0001){ref-type="fig"}b) and HO‐1 protein expression (Figure [1](#acel12837-fig-0001){ref-type="fig"}c,d). The increase in HO‐1 was evident in nonsenescent (P3) and senescent cells (P7) and was not significantly different between cells derived from S‐C or COPD subjects. In parallel experiments, cells were treated with hemin in the presence of heme oxygenase inhibitors ZnPPIX or QC‐15 and, while the two compounds did not change the levels of *HMOX1* gene expression compared with hemin alone (Figure [1](#acel12837-fig-0001){ref-type="fig"}a), they completely abolished the hemin‐mediated increase in heme oxygenase activity (Figure [1](#acel12837-fig-0001){ref-type="fig"}b). We note that at P3 and in the absence of hemin treatment, the *HMOX1* expression level was not different between fibroblasts from COPD patients and from S‐C. At P7, *HMOX1* expression was higher in fibroblasts from COPD patients as compared to S‐C but no difference in heme oxygenase activity and HO‐1 protein expression was observed (Figure [1](#acel12837-fig-0001){ref-type="fig"}a,b,c).

![Hemin induces gene, protein expression, and activity of heme oxygenase 1 (HO‐1). Fibroblasts from COPD patients (*n* = 14) and smoker controls (S‐C, *n* = 13) were treated chronically with either hemin (10 µM) alone or in the presence of inhibitors of HO‐1 activity: ZnPPIX (1 µM) or QC‐15 (15 µM) for 4 weeks. (a) Quantitative transcriptional expression of *HMOX1* by real‐time qPCR. (b) Heme oxygenase activity. (c) Quantification of HO‐1 protein expression by western blot. (d) Two examples of western blot. Data are presented as mean ± *SEM* in the whole Figure. \**p* \< 0.05 passage 7 (senescent stage) vs. passage 3 (nonsenescent stage), ^†^ *p* \< 0.05, ^††^ *p* \< 0.01 cells treated with hemin vs. cells treated with DMSO, ^\#^ *p* \< 0.05 cells treated with inhibitors of HO‐1 activity vs. cells treated with solvent](ACEL-17-e12837-g001){#acel12837-fig-0001}

2.3. Hemin prevents replicative senescence in fibroblasts from copd patients {#acel12837-sec-0005}
----------------------------------------------------------------------------

We next examined whether chronic exposure to hemin could attenuate replicative senescence and the secretome associated with the senescence phenotype. Fibroblasts from COPD patients were not different from S‐C at nonsenescent passage, but displayed senescence hallmarks at senescence passage: a lower senescence‐associated PDL (Figure [2](#acel12837-fig-0002){ref-type="fig"}a), an increased SA β‐gal staining (Figure [2](#acel12837-fig-0002){ref-type="fig"}b), and increased p16 and IL‐8 mRNA expression (Supporting Information Figures [S1](#acel12837-sup-0001){ref-type="supplementary-material"}, and [S2](#acel12837-sup-0001){ref-type="supplementary-material"}f) and increased p16 protein expression (S1), as compared to S‐C. In contrast, COPD fibroblasts showed an increase in p21 and P‐ATM protein expression which was higher than in smoker fibroblasts (Figure [2](#acel12837-fig-0002){ref-type="fig"}c). In addition, IL‐6 mRNA expression was similar to that of S‐C (Figure [2](#acel12837-fig-0002){ref-type="fig"}f). It has to be noted that the difference between COPD and S‐C in terms of SA β‐gal staining was evident at P5 (Figure [2](#acel12837-fig-0002){ref-type="fig"}b), whereas that concerning p16 and PDL was visible at P7 (Figure [2](#acel12837-fig-0002){ref-type="fig"}a, and Supporting Information Figure [S1](#acel12837-sup-0001){ref-type="supplementary-material"}). Such dissociation between markers of senescence was reported previously and could be related to diverse mechanisms underlining the evolution of senescence. Repeated exposures of fibroblasts to hemin protected against replicative senescence. Indeed, hemin further increased senescence‐associated PDL at P7 (Figure [2](#acel12837-fig-0002){ref-type="fig"}a) and decreased the induction of SA β‐gal (Figure [2](#acel12837-fig-0002){ref-type="fig"}b), p21 (Figure [2](#acel12837-fig-0002){ref-type="fig"}c), p16 (Supporting Information Figure [S1](#acel12837-sup-0001){ref-type="supplementary-material"}), P‐ATM (Figure [2](#acel12837-fig-0002){ref-type="fig"}d), IL‐6, and IL‐8 (Figure [2](#acel12837-fig-0002){ref-type="fig"}e,f). These effects were more pronounced in fibroblasts from COPD patients than from the S‐C group and were abolished in cells exposed to hemin in the presence of ZnPPIX or QC‐15 (Figure [2](#acel12837-fig-0002){ref-type="fig"}).

![Hemin attenuates replicative senescence in COPD fibroblasts. Fibroblasts from COPD patients (*n* = 14) and smoker controls (S‐C, *n* = 13) were treated chronically with either hemin (10 µM) alone or in the presence of inhibitors of HO‐1 activity: ZnPPIX (1 µM) or QC‐15 (15 µM) for 4 weeks. (a) The rate of proliferation was evaluated by the population doubling level (PDL). (b) Percentage of senescence‐associated (SA) β‐gal‐positive cells. (c, d) Quantification of p21 and P‐ATM obtained by immunostaining. Transcriptional expression of inflammatory mediators (IL‐6, IL‐8). (e, f) by real‐time qPCR in pulmonary fibroblasts. Data are presented as mean ± SEM in the whole Figure. \**p* \< 0.05, \*\**p* \< 0.01 passage 7 (senescent stage) vs. passage 3 (nonsenescent stage), ^†^ *p* \< 0.05 cells treated with hemin vs. cells treated with DMSO, ^§^ *p* \< 0.05 COPD vs. S‐C](ACEL-17-e12837-g002){#acel12837-fig-0002}

2.4. Hemin reduces ROS production linked to mitochondrial dysfunction {#acel12837-sec-0006}
---------------------------------------------------------------------

Since ROS play a major role in the induction of senescence and are increased in COPD (Barnes, [2017](#acel12837-bib-0004){ref-type="ref"}), we next investigated whether chronic exposure to hemin attenuated ROS production and analyzed cellular or mitochondrial ROS levels in fibroblasts from COPD and S‐C patients. Intracellular ROS production was statistically higher in fibroblasts from COPD patients as compared to controls at nonsenescent passage (Figure [3](#acel12837-fig-0003){ref-type="fig"}a), and replicative senescence (P7) was associated with a further increase in ROS levels in both COPD and S‐C fibroblasts. However, even in the senescent passage, fibroblasts from COPD displayed higher ROS levels than cells from S‐C (Figure [3](#acel12837-fig-0003){ref-type="fig"}a). We also observed a strongly enhanced mitochondrial ROS production at senescent passage, and again, we confirmed the differences between COPD and S‐C fibroblasts already noted for cellular ROS levels (Figure [3](#acel12837-fig-0003){ref-type="fig"}b). In order to confirm whether mitochondrial ROS play a role in the induction of fibroblast senescence, we treated cells with mitoquinol (an antioxidant which accumulates in mitochondria). Repeated exposures of COPD fibroblasts to mitoquinol reversed at senescent stage the lower PDL associated with senescence, and decreased the induction of SA β‐gal and p21 compared with untreated COPD fibroblasts (Supporting Information Figure [S6](#acel12837-sup-0001){ref-type="supplementary-material"}). Moreover, the exposure to mitoquinol abolished the difference between fibroblasts from COPD patients and S‐C group. No significant effects were observed in S‐C fibroblasts after treatment with mitoquinol. These data indicated that ROS, and especially mitochondrial ROS, are a factor associated with the senescent phenotype in S‐C and COPD fibroblasts.

![Hemin decreases total ROS and mROS linked to mitochondrial dysfunction Fibroblasts from COPD patients (*n* = 14) and smoker controls (S‐C, *n* = 13) were treated chronically with either Hemin (10 µM) alone or with inhibitors of HO‐1 activity: ZnPPIX (1 µM) or QC‐15 (15 µM) for 4 weeks. (a) Production of ROS was measured by DCFH‐DA fluorescence. Values are expressed as the percentage of control (ratio of fluorescence at 90 min over T0). (b) Production of mitochondrial ROS was measured by MitoSOX fluorescence. Values are expressed as the percentage of control (ratio of fluorescence at 15 min over T0). (c, d,) Bioenergetic parameters and extracellular acidification rate (ECAR, an index of glycolysis (f)) were measured using the Seahorse XF analyzer. (e) ATP levels, *n* = 7 in each group. Data are presented as mean ± SEM in the whole Figure. \**p* \< 0.05 passage 7 (senescent stage) vs. passage 3 (nonsenescent stage), ^§^ *p* \< 0.05 COPD passage 7 (vs. S‐C at passage 7, £*p* \< 0.05 COPD at passage 3 vs. S‐C at passage 3, ^†^ *p* \< 0.05 cells treated with hemin vs. cells treated with DMSO, ^§^ *p* \< 0.05 COPD vs. S‐C](ACEL-17-e12837-g003){#acel12837-fig-0003}

Since higher mitochondrial ROS suggests mitochondrial dysfunction, we investigated cellular metabolism and mitochondrial function by measuring respiration, glycolysis, and ATP levels in S‐C and COPD cells at P3 and P7. At nonsenescent passage, we observed a general depression in oxygen consumption in fibroblasts from COPD patients compared to S‐C, with a decrease in basal and maximal respiration (Figure [3](#acel12837-fig-0003){ref-type="fig"}c,d and Supporting Information Figure [S2](#acel12837-sup-0001){ref-type="supplementary-material"}). At senescent stages, these differences were exacerbated (Figure [3](#acel12837-fig-0003){ref-type="fig"}c,d) but we highlight the fact that also fibroblasts from S‐C at P7 exhibited an inhibited mitochondrial function compared to S‐C cells at P3. A similar profile was detected for glycolysis (ECAR, Figure [3](#acel12837-fig-0003){ref-type="fig"}f), emphasizing that the metabolic status of COPD fibroblast was compromised even at nonsenescent passage. Accordingly, ATP levels were lower in COPD fibroblasts at P3 and were considerably decreased in both S‐C and COPD cells at P7 (Figure [3](#acel12837-fig-0003){ref-type="fig"}e), as expected for senescence stages. These data suggest that senescence alone, whether occurring in S‐C or COPD fibroblasts, is accompanied by decreased mitochondrial activity, that this phenomenon is exacerbated in COPD as compared to S‐C fibroblasts and that the increased production of ROS in fibroblasts from COPD patients is linked to a mitochondrial dysfunction.

As observed for replicative senescence, repeated exposure to hemin decreased cellular and mitochondrial ROS production in COPD fibroblasts (Figure [3](#acel12837-fig-0003){ref-type="fig"}a,b), with a parallel recovery in mitochondrial respiration, spare respiratory capacity, glycolysis, and ATP production at P7 (Figure [4](#acel12837-fig-0004){ref-type="fig"}a,b,c,d, and Supporting Information Figure [S3](#acel12837-sup-0001){ref-type="supplementary-material"}). A similar improvement in respiration was also induced by hemin in S‐C senescent fibroblasts (Figure [4](#acel12837-fig-0004){ref-type="fig"}a,b). These effects were abolished by concomitant administration of hemin with either ZnPPIX or QC‐15 (Figures [3](#acel12837-fig-0003){ref-type="fig"}a,b, and [4](#acel12837-fig-0004){ref-type="fig"}). Interestingly, while cotreatment of hemin with QC‐15 prevented the rescue of mitochondrial respiration in COPD senescent fibroblasts, QC‐15 did not affect bioenergetic parameters and glycolysis (S4, data not shown), implying that the effect of hemin and HO‐1 induction is more specific toward modulation of mitochondrial function.

![Hemin protects against mitochondria dysfunction. Fibroblasts from COPD patients (*n* = 14) and smoker controls (S‐C, *n* = 13) were treated chronically with either Hemin (10 µM) alone or with an inhibitor of HO‐1 activity: QC‐15 (15 µM) for 4 weeks. Bioenergetic parameters (a) basal respiration, (b) maximum respiration, (c) ATP turnover were measured using the Seahorse XF analyzer. (d) ATP levels. Data are presented as mean ± SEM in the whole Figure. \**p* \< 0.05 passage 7 (senescent stage) vs. passage 3 (nonsenescent stage), ^†^ *p* \< 0.05 cells treated with hemin vs. cells treated with DMSO, ^§^ *p* \< 0.05 COPD vs. S‐C](ACEL-17-e12837-g004){#acel12837-fig-0004}

2.5. Hemin modulates mitochondrial biogenesis and improves mitophagy in COPD fibroblasts {#acel12837-sec-0007}
----------------------------------------------------------------------------------------

To further investigate the mechanisms that contribute to the improvement of mitochondria function by hemin, we analyzed mitophagy and mitochondrial biogenesis, two related cell pathways that may be affected by senescence and COPD. We first assessed mitochondrial content in S‐C and COPD fibroblasts at nonsenescent and senescent stages. We found that mitochondrial mass was higher in fibroblasts from COPD patients as compared to S‐C at nonsenescent passage (Figure [5](#acel12837-fig-0005){ref-type="fig"}a). Mitochondrial mass significantly increased in S‐C fibroblasts at senescent passage, whereas it remained unchanged in COPD fibroblasts. As a consequence, the difference observed between the two groups before senescence was lost at the senescence passage (Figure [5](#acel12837-fig-0005){ref-type="fig"}a). In addition, we evaluated autophagy by determining the expression of p62, LC3I, and II (Supporting Information Figure [S5](#acel12837-sup-0001){ref-type="supplementary-material"}). The ratio LC3II/I was not modified whatever the fibroblasts or treatment considered. Concerning the expression of p62, we noted a slight but not significant increase in COPD fibroblasts at nonsenescent stage. However, this effect was lost at senescent passage. Hemin did not modify the expression level of these three proteins. These different experiments show that the autophagic flow is not apparently modified in fibroblasts from smokers and COPD patients. However, staining with an antibody against LC3 (an autophagosome marker) colocalized with MitoSOX Red (used as a marker of mitochondria) in fibroblasts from COPD patients at senescent stage indicated autophagosome accumulation (Supporting Information Figure [S5](#acel12837-sup-0001){ref-type="supplementary-material"}c), confirming a defect of mitophagy in COPD fibroblasts. Hemin abolished this colocalization, suggesting a restoration of mitophagy in these cells. Interestingly, the mRNA expression of NRF1 and PGC‐1α (the master gene of mitochondrial biogenesis) was significantly higher in COPD fibroblasts compared with controls at nonsenescent passage, although this difference was less pronounced at senescent passage for PGC‐1α (Figure [5](#acel12837-fig-0005){ref-type="fig"}c,b). These results advocate for a compensatory effect of mitochondria biogenesis in fibroblasts from COPD patients at nonsenescent stage. To assess this idea, we treated fibroblasts with an inhibitor of mitochondrial biogenesis in long‐term culture. This treatment led to the death of cells from COPD patient, reinforcing this hypothesis (data not shown).

![Hemin decreases the biogenesis of mitochondria and increases mitophagy in COPD fibroblasts. Pulmonary fibroblasts derived from COPD patients (*n* = 14) and smoker controls (S‐C, *n* = 13) were treated chronically with either hemin (10 µM) alone or in the presence of inhibitors of heme oxygenase activity: ZnPPIX (1 µM) or QC‐15 (15 µM). (a) Mitochondria mass detection was performed by using acridine orange 10‐nonyl bromide staining. Cells were analyzed with flow cytometry. (b, c) Quantitative transcriptional expression of gene involved in biogenesis (NRF‐1 and PGC1α) by real‐time qPCR in pulmonary fibroblasts. (d, e) Expression of proteins involved in mitophagy (PARKIN and PINK‐1) by western blot. Data are presented as mean ± SEM in the whole Figure. \**p* \< 0.05, passage 7 (senescent stage vs. passage 3 (nonsenescent stage), ^†^ *p* \< 0.05 cells treated with hemin vs. cells treated with DMSO, ^§^ *p* \< 0.05 COPD vs. S‐C](ACEL-17-e12837-g005){#acel12837-fig-0005}

We analyzed mitophagy by examining the protein expression of Parkin and PINK‐1. We observed that protein expression of Parkin was dramatically decreased in COPD compared to S‐C fibroblasts at nonsenescent passage (Figure [5](#acel12837-fig-0005){ref-type="fig"}d). Parkin expression significantly decreased in S‐C fibroblasts at senescent passage, whereas it remained unchanged in COPD fibroblasts. No changes in PINK‐1 expression were observed in both groups at nonsenescent and senescent passages (Figure [5](#acel12837-fig-0005){ref-type="fig"}e).

Chronic exposure of cells to hemin led to a decrease in mitochondrial mass in COPD fibroblasts at senescent passage (Figure [5](#acel12837-fig-0005){ref-type="fig"}a). This effect was accompanied by lower NRF1 expression (Figure [5](#acel12837-fig-0005){ref-type="fig"}b) along with a significant increase in PINK1 protein expression (Figure [5](#acel12837-fig-0005){ref-type="fig"}e) and was not observed at nonsenescence stage or in S‐C cells. Importantly, cotreatment with ZnPPIX or QC‐15 completely abolished this response.

Collectively, these results suggest that COPD fibroblasts are characterized by an impaired mitophagy at nonsenescent passage as evidenced by an increased mitochondrial mass and compensatory mitochondrial biogenesis. This phenomenon persisted at senescent passage and was associated with increased senescence in COPD cells. Continuous exposure to nontoxic levels of hemin prevented these events by ameliorating mitochondrial function (Figure [6](#acel12837-fig-0006){ref-type="fig"}).

![Senescence prevention by HO‐1 activation. (a) Mitochondrial dysfunction, characterized by a decrease in basal respiration and an increase in mROS production, is observed at nonsenescent passage in COPD lung fibroblasts. At the same time, defective mitophagy is also present (increase in mitochondria mass and decrease in Parkin), which ensures the maintenance of malfunctional mitochondria. To compensate for this effect, fibroblasts increase mitochondria biogenesis. (b) At the onset of senescence state, mitochondria dysfunction is exacerbated as evidenced by a further decrease in basal and maximal respiration, ATP turnover, and increased mROS production. However, mitochondria biogenesis compensatory pathway is lost. All of this contributes to the induction of senescence in senescent lung fibroblasts. (c) The induction of HO‐1 by hemin exerts a protective effect on mitochondria function (improvement of all parameters) and increases mitophagy (decrease in mitochondria mass and increase in PINK‐1). Thus, HO‐1 prevents the induction of senescence in COPD fibroblasts by protecting against mitochondria dysfunction](ACEL-17-e12837-g006){#acel12837-fig-0006}

3. DISCUSSION {#acel12837-sec-0008}
=============

The main results of this study are the following: (a) At nonsenescent passage, compared to fibroblasts from control smokers, COPD fibroblasts display hallmarks of mitochondrial dysfunction (increased mitochondrial ROS production and decreased respiration, glycolysis, and ATP levels) accompanied by impaired mitophagy as evidenced by an increased mitochondrial mass, compensatory mitochondrial biogenesis, and decreased expression of Parkin protein; (b) these phenomena were aggravated at senescent stage in both smoker and COPD fibroblasts and were associated in this last group to an increased replicative senescence; and (c) hemin treatment attenuated mitochondrial dysfunction, restored mitophagy, and suppressed the increased senescence in COPD fibroblasts; these effects were abrogated by two different and not chemically related HO inhibitors. Collectively, these results demonstrate that senescence of pulmonary COPD fibroblasts is associated with mitochondrial dysfunction, suggesting a close relationship between an impaired mitophagy, accumulation of dysfunctional mitochondria producing excessive amount of ROS, and aggravation of replicative senescence. The protective effects of hemin against COPD fibroblasts senescence are likely the consequence of a primary effect of HO‐1 induction restoring the defective mitophagy of these cells.

Our results showing mitochondrial dysfunction in fibroblasts from COPD patients even at nonsenescent passage are consistent with data published in the literature showing that bronchial epithelial cells from COPD patients exhibited swollen, elongated mitochondria with fragmentation, and disruption of cristae (Hoffmann et al., [2013](#acel12837-bib-0014){ref-type="ref"}). Since fibroblasts were isolated from lung samples of patients suffering from lung cancer, a cancer‐related fibroblast phenotype could explain the differences between COPD and control smokers. However, we think this possibility unlikely because: (a) Smoker controls and COPD patients suffered from similar cancer histological types, (b) biopsies were harvested at a distance from the tumor and were verified to be free of malignant cells, and (c) primary cultures of lung fibroblasts did not exhibit Cancer Associated Fibroblasts markers (data not shown). Cigarette smoke can trigger mitochondrial dysfunction in COPD fibroblasts since lung epithelial cells and fibroblasts exposed to cigarette smoke exhibit an increase in mitochondrial ROS, reduced ATP levels, and changes in mitochondria structure (Ahmad et al., [2015](#acel12837-bib-0001){ref-type="ref"}), (Hoffmann et al., [2013](#acel12837-bib-0014){ref-type="ref"}). However, other factors probably contribute to mitochondrial dysfunction in COPD cells since in the present study, the smoking history of COPD and control smokers was similar. A COPD specific impaired mitophagy could be one of these mechanisms. Indeed, a decreased Parkin expression was reported in lung tissues of COPD patients (Ahmad et al., [2015](#acel12837-bib-0001){ref-type="ref"}; Ito et al., [2015](#acel12837-bib-0018){ref-type="ref"}). Interestingly, this reduction was correlated with a decrease in lung function in COPD patients (Ito et al., [2015](#acel12837-bib-0018){ref-type="ref"}). In our study, we noted the same correlation between protein expression of Parkin and FEV1 in fibroblasts from COPD patient (data not shown). Identification of the mechanism(s) underlying a specific alteration in mitophagy in COPD fibroblasts is beyond the scope of the present study and needs further investigation.

Our results show that, independent from the mechanism underlying impaired mitophagy in COPD, this phenomenon and the associated mitochondrial dysfunction clearly anticipate the pronounced replicative senescence of COPD cells. This is the first demonstration of an association between mitochondrial dysfunction and replicative senescence in COPD. Studies performed in cells exposed to cigarette smoke support a cause--effect relationship between impaired mitophagy, mitochondrial dysfunction, and increased accelerated senescence in COPD. In fact, Ahmad and coworkers (Ahmad et al., [2015](#acel12837-bib-0001){ref-type="ref"}) showed that overexpression of Parkin reduces cigarette smoke‐induced DNA damage and cellular senescence when used in combination with a scavenger of mitochondria ROS. In addition, Ito and coworkers demonstrated that the knockdown of *Pink1* or *Parkin* in human bronchial epithelial cells (HBECs) enhanced cellular senescence induced by cigarette smoke exposure (Ito et al., [2015](#acel12837-bib-0018){ref-type="ref"}). Our findings showing a protective effect of hemin against both impaired mitophagy and mitochondrial dysfunction and consecutive prevention of replicative senescence further support a cause--effect relationship between the two phenomena in COPD. The role of mitochondrial ROS is also corroborated by the reduction of senescent markers in mitoquinol‐exposed COPD cells.

Hemin could protect against mitochondrial dysfunction by several mechanisms. The first is related to the increased HO‐1 activity and heme‐derived products, since the protective effects of hemin were abolished by two chemically different inhibitors of heme oxygenase activity (ZnPPIX and QC‐15). HO‐1 can induce mitophagy pathways through nuclear respiratory factor‐dependent (NRF‐1‐dependent) expression of the PINK1/PARK2 genes, as demonstrated recently by Suliman, Keenan, and Piantadosi ([2017](#acel12837-bib-0030){ref-type="ref"}). This effect extends the described activation of mitochondrial biogenesis by CO produced by HO‐1 (Suliman, Carraway, Tatro, & Piantadosi, [2007](#acel12837-bib-0029){ref-type="ref"}). Nevertheless, we observed a decreased expression of NRF‐1 in fibroblasts from COPD patients treated with hemin, suggesting that another mechanism could be involved. Indeed, cytoplasmic p53, which accumulates in senescence, interacts with Parkin and prevents its translocation to dysfunctional mitochondria, thus suppressing mitophagy (Ahmad et al., [2015](#acel12837-bib-0001){ref-type="ref"}; Hoshino et al., [2013](#acel12837-bib-0016){ref-type="ref"}). Similarly, expression of PINK‐1 is low in aging lungs, which participate in the deletion of mitophagy (Bueno et al., [2015](#acel12837-bib-0005){ref-type="ref"}). HO‐1 could decrease the accumulation of p53 and release Parkin. Moreover, hemin increased the level of PINK‐1 in COPD fibroblasts, which will participate in the restoration of mitophagy. An additional mechanism could involve the activation of AMPK, which has been shown recently to decrease senescence and inflammation in human bronchial and small airway epithelial cells exposed to cigarette smoke and in a mice model of emphysema (Cheng et al., [2017](#acel12837-bib-5000){ref-type="ref"}). Indeed, prophylactic administration of an AMPK activator reduced emphysema, inflammatory responses, and cellular senescence in mice treated with elastase. In our experiments, the expression of AMPK in COPD fibroblasts decreased at senescent stage and was increased by chronic exposures to hemin, suggesting a role of this protein in the attenuation of senescence in COPD fibroblasts (data not shown).

In conclusion, the present results show that HO‐1, through its induction by hemin, protects against mitochondria dysfunction by restoring mitophagy and attenuating senescence in COPD fibroblasts. These results have important implications in terms of a better understanding the mechanisms of cell senescence in COPD. Furthermore, they can set up the basis for the development of new therapeutic strategies in COPD based on counteracting senescence through modulation of HO‐1.

4. EXPERIMENTAL PROCEDURES {#acel12837-sec-0009}
==========================

4.1. Materials {#acel12837-sec-0010}
--------------

Hemin and ZnPPIX were purchased from Sigma (Saint Quentin Fallavier, France) and Frontier Scientific (Distributor: Inochem, Ltd, Carnforth, Lancashire, United Kingdom), respectively. QC‐15 was a kind gift from Prof Kanji Nakatsu from Queen's University, Kingston, Ontario, Canada. All other reagents were purchased from Sigma unless otherwise stated.

4.2. Patients and cells {#acel12837-sec-0011}
-----------------------

Primary lung fibroblasts were isolated by the explants technique (Normand & Karasek, [1995](#acel12837-bib-0023){ref-type="ref"}) from lung specimens obtained for lung tumor resection from 14 patients with COPD and 13 subjects without clinical, morphologic, or functional signs of COPD (control subjects; Table [1](#acel12837-tbl-0001){ref-type="table"}). Classification of COPD severity was based on the 2003 Global Initiative for Chronic Obstructive Lung Disease criteria (Rabe et al., [2007](#acel12837-bib-0028){ref-type="ref"}). Informed consent was obtained from all patients, and the study was approved by the "Comité de Protection des Personnes Ile de France IX."

4.3. Cell treatments {#acel12837-sec-0012}
--------------------

In these experiments, fibroblasts were used at a nonsenescent stage (passage three, P3) until a senescent stage (passage seven, P7). We verified in preliminary experiments that the concentration of all pharmacological compounds used in our studies did not alter the viability of cells by using MTT and LDH assays (data not shown).

To evaluate whether chronic exposure of nonsenescent fibroblasts to hemin (an inducer of HO‐1 and substrate for heme oxygenase activity) could prevent replicative senescence in long‐term cultures, fibroblasts were treated with 10 µM hemin every 2 days for 4 weeks. In parallel experiments, the effect of hemin was blocked by daily exposure of cells to 1 µM ZnPPIX, a general inhibitor of heme oxygenase activity, or 15 µM QC‐15, a more selective inhibitor of HO‐1 enzymatic activity. Gene expression levels of HO‐1, protein expression, and heme oxygenase activity were studied. Senescence was characterized by measuring cumulative population doubling levels (PDLs; Holz et al., [2004](#acel12837-bib-0015){ref-type="ref"}), senescence‐associated β‐galactosidase activity (SA β‐gal; Dimri, [2005](#acel12837-bib-0010){ref-type="ref"}), and the expression of P‐ATM, p21 by immunofluorescence, and p16 by western blot and real‐time quantitative polymerase chain reaction analysis. Markers of inflammation (IL‐6, IL‐8) were assessed by real‐time quantitative polymerase chain reaction analysis.

Analysis of senescence markers, HO‐1 gene, and protein expression and ROS production were performed in all patients, and others analyses were performed in subgroups representative of the whole population.

4.4. Measurement of oxidative stress by DCFH‐DA assay and mitochondrial ROS production by mitoSOX red assay {#acel12837-sec-0013}
-----------------------------------------------------------------------------------------------------------

Endogenous ROS were quantified by oxidation of 2′,7′ dichlorofluorescin diacetate (DCFH‐DA) into 2′,7′ dichlorofluorescin (Sigma, Saint Quentin Fallavier, France). Briefly, cells were cultivated in six‐well culture plates and treated either with hemin alone or hemin in the presence of QC‐15 or ZnPPIX. Cells were also treated with 250 µM H~2~O~2~ as a positive control (data not shown). Cells were incubated with 20 µM DCFH‐DA for 30 min at 37°C and fluorescence recorded for 90 min. Results were expressed as a ratio of fluorescence at 90 min over fluorescence at T0.

The detection of mitochondrial superoxide was assessed by oxidation of MitoSOX Red (Life Technologies). Once in the mitochondria, the MitoSOX reagent is oxidized by superoxide and exhibits red fluorescence. The fluorescent product is measured fluorometrically at 580 nm after excitation at 500 nm. Cells were incubated with 5 µM MitoSOX Red for 10 min at 37°C and fluorescence recorded for 15 min. The results were expressed as a ratio of fluorescence at 15 min over fluorescence at T0.

4.5. Heme oxygenase activity assay {#acel12837-sec-0014}
----------------------------------

Cells cultured in 100‐mm diameter petri dishes were collected at passage three or seven after the following treatments: (a) medium alone, (b) hemin (10 μM) added to the culture medium every 2 days, and (c) the combination of hemin and the inhibitors of HO‐1 activity ZnPPIX (1 µM) or QC‐15 (15 µM) added to the medium every day. Samples were incubated with the substrate hemin, NADPH, liver cytosol (a source of biliverdin reductase), and other cofactors to sustain heme oxygenase activity. The reaction was allowed to proceed for 1 hr at 37°C in the dark and was terminated by addition of chloroform to extract the bilirubin produced. Bilirubin was measured spectrophotometrically as described before and calculated in picomoles bilirubin/mg protein/hr (Foresti & Motterlini, [1999](#acel12837-bib-0011){ref-type="ref"}).

4.6. Cellular bioenergetic analysis using the seahorse bioscience XF analyzer {#acel12837-sec-0015}
-----------------------------------------------------------------------------

Analysis of bioenergetic parameters was performed in intact cells using the XF24 analyzer from Seahorse Bioscience (Billerica, MA, USA). Oxygen consumption rate (OCR), which indicates mitochondrial respiration, and extracellular acidification rate (ECAR), an index of glycolysis, were measured in real time in human fibroblasts collected from S‐C or COPD patients after various treatments. Nonsenescent and senescent cells were used for these studies. An optimal cell density of 45,000 cells/well was determined in preliminary experiments. A classical Mito Stress test was performed according to the following procedure: (a) Basal respiration was measured in unbuffered medium; (b) oligomycin (1 µg/ml final concentration), an inhibitor of ATP synthesis, was injected to determine respiration linked to ATP production; (c) the uncoupler carbonyl cyanide 4‐(trifluoromethoxy) phenylhydrazone (FCCP, 0.7 µM final concentration) was added to measure maximal respiration; and (d) rotenone/antimycin A (1 µM final) was applied in combination with block respiration due to simultaneous inhibition of complexes I and III, respectively. Parameters of mitochondrial function were calculated from the respiratory curves as described previously (Wilson et al., [2017](#acel12837-bib-0032){ref-type="ref"}).

4.7. ATP assay {#acel12837-sec-0016}
--------------

Cellular ATP levels were assessed at the end of the Seahorse experiments. ATP production was measured using the ATPLite™ bioluminescent assay kit (Perkin Elmer, Courtaboeuf, France) following the manufacturer's instructions.

4.8. Mitochondrial staining {#acel12837-sec-0017}
---------------------------

Determination of mitochondrial content was performed using acridine orange 10‐nonyl bromide (NAO), which binds to cardiolipin present in mitochondria. Cells at P3 or P7 subjected to different treatments were fixed for 30 min with 4% paraformaldehyde in PBS at 37°C and incubated for 30 min with 1 µM NAO at 37°C in the dark. After two washes with PBS, cells were analyzed with flow cytometry using a CyAn™ ADP LX7 Analyzer (Beckman Coulter).

4.9. Statistical analysis {#acel12837-sec-0018}
-------------------------

Data were analyzed with GraphPad Prism 4.0 (La Jolla, CA). Comparisons between groups were performed with Kruskal--Wallis' nonparametric analysis of variance test followed by two‐by‐two comparisons with Mann--Whitney's *U* test when a significant difference was detected. *p* \< 0.05 was considered statistically significant.
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